FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038716828> ?p ?o ?g. }

• W2038716828 endingPage "464" @default.
• W2038716828 startingPage "457" @default.
• W2038716828 abstract "Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC). Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. This was an open-label, single-arm, multicenter, Phase II study to evaluate the efficacy and safety of nab-paclitaxel plus lapatinib in women with HER2 over-expressing MBC who had received no more than one prior chemotherapeutic regimen. The primary efficacy endpoint was the overall response rate (ORR). This was defined as the percentage of patients having either a complete response (CR) or partial response (PR). Secondary efficacy endpoints included progression-free survival (PFS), overall survival, duration of response (DoR), time to response (TTR), and time to progression (TTP). Investigator-assessed ORR was 53 % (n = 32, 95 % confidence interval (CI): 40.7-66.0) with the majority of patient responses demonstrating a PR (47 %). Four (7 %) patient responses demonstrated a CR, and ten (17 %) a stable disease. The median Kaplan-Meier estimate of investigator-assessed PFS, DoR, TTR, and TTP was 39.7 weeks (95 % CI 34.1-63.9), 48.7 weeks (95 % CI 31.7-57.1), 7.8 weeks (95 % CI 7.4-8.1), and 41 weeks (95 % CI 39.1-64.6), respectively. Lapatinib 1,000 mg with nab-paclitaxel 100 mg/m(2) IV is feasible with manageable and predictable toxicity and an ORR of 53 % comparing favorably with other HER2-based combinations in this setting." @default.
• W2038716828 created "2016-06-24" @default.
• W2038716828 creator A5003279484 @default.
• W2038716828 creator A5010136972 @default.
• W2038716828 creator A5013955755 @default.
• W2038716828 creator A5016756915 @default.
• W2038716828 creator A5017228186 @default.
• W2038716828 creator A5022422153 @default.
• W2038716828 creator A5032766035 @default.
• W2038716828 creator A5035910746 @default.
• W2038716828 creator A5053359739 @default.
• W2038716828 creator A5089040548 @default.
• W2038716828 date "2012-12-08" @default.
• W2038716828 modified "2023-09-26" @default.
• W2038716828 title "Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen" @default.
• W2038716828 cites W1964321121 @default.
• W2038716828 cites W1992353283 @default.
• W2038716828 cites W1999513758 @default.
• W2038716828 cites W2033779255 @default.
• W2038716828 cites W2061563172 @default.
• W2038716828 cites W2064087555 @default.
• W2038716828 cites W2082326948 @default.
• W2038716828 cites W2095156669 @default.
• W2038716828 cites W2110444464 @default.
• W2038716828 cites W2112621891 @default.
• W2038716828 cites W2117972559 @default.
• W2038716828 cites W2133503038 @default.
• W2038716828 cites W2136704455 @default.
• W2038716828 cites W2138692412 @default.
• W2038716828 cites W2141393790 @default.
• W2038716828 cites W2146384083 @default.
• W2038716828 cites W2149908785 @default.
• W2038716828 cites W2153017356 @default.
• W2038716828 cites W2161574596 @default.
• W2038716828 cites W2164190676 @default.
• W2038716828 cites W2165948908 @default.
• W2038716828 cites W2170241131 @default.
• W2038716828 cites W2318605753 @default.
• W2038716828 doi "https://doi.org/10.1007/s10549-012-2341-9" @default.
• W2038716828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3539071" @default.
• W2038716828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23224144" @default.
• W2038716828 hasPublicationYear "2012" @default.
• W2038716828 type Work @default.
• W2038716828 sameAs 2038716828 @default.
• W2038716828 citedByCount "29" @default.
• W2038716828 countsByYear W20387168282013 @default.
• W2038716828 countsByYear W20387168282014 @default.
• W2038716828 countsByYear W20387168282015 @default.
• W2038716828 countsByYear W20387168282016 @default.
• W2038716828 countsByYear W20387168282019 @default.
• W2038716828 countsByYear W20387168282020 @default.
• W2038716828 countsByYear W20387168282021 @default.
• W2038716828 countsByYear W20387168282022 @default.
• W2038716828 crossrefType "journal-article" @default.
• W2038716828 hasAuthorship W2038716828A5003279484 @default.
• W2038716828 hasAuthorship W2038716828A5010136972 @default.
• W2038716828 hasAuthorship W2038716828A5013955755 @default.
• W2038716828 hasAuthorship W2038716828A5016756915 @default.
• W2038716828 hasAuthorship W2038716828A5017228186 @default.
• W2038716828 hasAuthorship W2038716828A5022422153 @default.
• W2038716828 hasAuthorship W2038716828A5032766035 @default.
• W2038716828 hasAuthorship W2038716828A5035910746 @default.
• W2038716828 hasAuthorship W2038716828A5053359739 @default.
• W2038716828 hasAuthorship W2038716828A5089040548 @default.
• W2038716828 hasBestOaLocation W20387168281 @default.
• W2038716828 hasConcept C121608353 @default.
• W2038716828 hasConcept C126322002 @default.
• W2038716828 hasConcept C143998085 @default.
• W2038716828 hasConcept C203092338 @default.
• W2038716828 hasConcept C2775930923 @default.
• W2038716828 hasConcept C2776694085 @default.
• W2038716828 hasConcept C2777292972 @default.
• W2038716828 hasConcept C2777329042 @default.
• W2038716828 hasConcept C2777511904 @default.
• W2038716828 hasConcept C2778336483 @default.
• W2038716828 hasConcept C2779786085 @default.
• W2038716828 hasConcept C2779880527 @default.
• W2038716828 hasConcept C2779984678 @default.
• W2038716828 hasConcept C2780739268 @default.
• W2038716828 hasConcept C2781413609 @default.
• W2038716828 hasConcept C31760486 @default.
• W2038716828 hasConcept C530470458 @default.
• W2038716828 hasConcept C535046627 @default.
• W2038716828 hasConcept C71924100 @default.
• W2038716828 hasConceptScore W2038716828C121608353 @default.
• W2038716828 hasConceptScore W2038716828C126322002 @default.
• W2038716828 hasConceptScore W2038716828C143998085 @default.
• W2038716828 hasConceptScore W2038716828C203092338 @default.
• W2038716828 hasConceptScore W2038716828C2775930923 @default.
• W2038716828 hasConceptScore W2038716828C2776694085 @default.
• W2038716828 hasConceptScore W2038716828C2777292972 @default.
• W2038716828 hasConceptScore W2038716828C2777329042 @default.
• W2038716828 hasConceptScore W2038716828C2777511904 @default.
• W2038716828 hasConceptScore W2038716828C2778336483 @default.
• W2038716828 hasConceptScore W2038716828C2779786085 @default.
• W2038716828 hasConceptScore W2038716828C2779880527 @default.
• W2038716828 hasConceptScore W2038716828C2779984678 @default.
• W2038716828 hasConceptScore W2038716828C2780739268 @default.

• next